We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

50 hedge funds and large institutions have $19.2M invested in Spyre Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.15% less ownership

Funds ownership: 2.92% → 2.77% (-0.15%)

9% less funds holding

Funds holding: 55 → 50 (-5)

15% less capital invested

Capital invested by funds: $22.6M → $19.2M (-$3.38M)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
12
Reduced
11
Closed
13
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.67M
2
PVI
Pura Vida Investments
New York
+$754K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$663K
4
NCM
Nantahala Capital Management
Connecticut
+$647K
5
SFM
Sphera Funds Management
Israel
+$317K

Top Sellers

Rank Fund Capital Flow
1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$1.34M
2
GPP
Great Point Partners
Connecticut
-$1.31M
3
SCM
Sio Capital Management
New York
-$1.2M
4
Goldman Sachs
Goldman Sachs
New York
-$482K
5
BlackRock
BlackRock
New York
-$278K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$2.41M – – –
NCM
2
Nantahala Capital Management
Connecticut
$2.07M +$647K +36,021 +24%
SCM
3
Suvretta Capital Management
New York
$1.83M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$1.54M – – –
BBA
5
Baker Bros. Advisors
New York
$1.53M – – –
Millennium Management
6
Millennium Management
New York
$1.41M +$1.67M +92,672 +284%
SCM
7
Sio Capital Management
New York
$1.35M -$1.2M -66,543 -36%
Vanguard Group
8
Vanguard Group
Pennsylvania
$899K +$79.2K +4,408 +6%
O
9
OrbiMed
New York
$809K – – –
ACM
10
Aisling Capital Management
New York
$761K – – –
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$675K – – –
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$625K +$663K +36,913 +197%
PVI
13
Pura Vida Investments
New York
$472K +$754K +41,948 New
SB
14
Samsara BioCapital
California
$398K – – –
GTC
15
Ghost Tree Capital
New York
$360K -$144K -8,000 -20%
BlackRock
16
BlackRock
New York
$291K -$278K -15,469 -37%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$270K +$148K +8,257 +52%
SFM
18
Sphera Funds Management
Israel
$198K +$317K +17,633 New
Two Sigma Investments
19
Two Sigma Investments
New York
$177K +$209K +11,602 +280%
Assenagon Asset Management
20
Assenagon Asset Management
Luxembourg
$143K – – –
Two Sigma Advisers
21
Two Sigma Advisers
New York
$123K -$98.6K -5,484 -33%
UOTTAIMCU
22
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$111K – – –
A
23
Abingworth
United Kingdom
$108K – – –
State Street
24
State Street
Massachusetts
$96.7K +$40.3K +2,240 +35%
Renaissance Technologies
25
Renaissance Technologies
New York
$68K -$71K -3,948 -40%
1
2 3

SYRE Hedge Fund Activity: Q4 2022 in Review

50 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2022, worth a combined $19.2M — down 15% from $22.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of SYRE and 8 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, adding an estimated $1.67M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $1.34M sold.

  • 50 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2022, down from 55 in Q3 2022.
  • Funds reported $19.2M of Spyre Therapeutics stock for Q4 2022, down 15% quarter-over-quarter.
  • 8 funds opened new Spyre Therapeutics positions in Q4 2022 and 13 closed out, a net change of -5 holders.
  • The largest Spyre Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $1.67M added.
  • The largest Spyre Therapeutics seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $1.34M sold.

Based on aggregated 13F filings for Q4 2022.